Pharmacological therapy for Type 2 (non-insulin-dependent) diabetes mellitus aims at controlling hyperglycaemia to delay or prevent complications associated with the disease. Most patients with Type 2 diabetes present with both stimulated insulin deficiency and insulin resistance. In general, the former can manifest as postprandial hyperglycaemia and the latter as fasting hyperglycaemia, though a definitive association has not been established. Emerging data show a high failure rate of long-term monotherapy and establishes the significance of mealtime glycaemia and the role of postprandial glucose excursions in the development and progression of vascular complications. To overcome such failures of monotherapy and to address the different underlying defects of the pathology of Type 2 diabetes, a combined therapy of oral antidiabetic agents with complementary modes of action should be considered. Currently used oral antidiabetic agents such as sulphonylureas, biguanides (metformin) and the thiazolidinediones (rosiglitazone, pioglitazone) commonly target fasting hyperglycaemia and have limited additive effects on postprandial glycaemia. In contrast, α-glucosidase inhibitors can reduce postprandial hyperglycaemia but gastrointestinal side effects restrict their use. The development of new agents to control postprandial glucose excursions could be considered as an additional objective for the management of Type 2 diabetes. To this end new short-acting enhancers of insulin secretion such as repaglinide (benzoic acid derivative) and nateglinide (amino acid derivative) have been developed. The combination of such agents with other complementary modes of action, e.g. an insulin sensitizer, could target better major underlying defects of Type 2 diabetes and thereby provide a better approach for controlling the entire glycaemic risk. [Diabetologia (2003) 
glycaemia to reduce the risk of microvascular and macrovascular complications. The current guidelines for glycaemic control in Type 2 diabetes set aggressive targets of HbA 1c of less than 7% or even less than 6.5% [1, 2] . Such challenging targets suggest that clinicians need to re-evaluate their treatment strategies to attain near-normal HbA 1c values. For example, good glycaemic control (HbA 1c <7%) has been achieved by only about 25% of patients treated with metformin monotherapy with a mean baseline HbA 1c of 8.2 to 8.4% [3, 4] . These data, and those from other clinical studies, suggest that combination therapy may be required to reach glycaemic control targets in patients who have early Type 2 diabetes (i.e. HbA 1c ≤9%).
Guidelines for the management of Type 2 (non-insulindependent) diabetes mellitus have recently been modified to take into account the need to attain near normal
The introduction of multiple classes of oral antidiabetic agents that act differentially to correct the metabolic defects which characterise Type 2 diabetes has greatly expanded the potential for combination therapy. An understanding of the metabolic pathogenesis of diabetes and the pharmacological mechanisms of action of antidiabetic drugs can facilitate their rational use.
Both impaired beta-cell function and increased insulin resistance occur in patients with IGT and in those with Type 2 diabetes. In IGT and early Type 2 diabetes the early phase of insulin secretion is lost, mainly resulting in the characteristic increased postprandial glucose. Increased insulin resistance also frequently occurs in people who are obese and is associated with the metabolic syndrome [3] .
The traditional focus of antidiabetic agents was mainly to reduce fasting plasma glucose (FPG) but convincing evidence now exists showing the importance of controlling both postprandial and fasting hyperglycaemia [1, 2, 3, 4] . Postprandial hyperglycaemia, when the multiple homeostatic mechanisms that minimise glucose excursions and restore euglycaemia after a meal are blunted, is one of the earliest abnormalities of glucose homeostasis in patients with IGT and Type 2 diabetes. In these patients, the early phase of insulin secretion in response to a glucose challenge is lost and, although overall insulin exposure is not altered, increases in postprandial blood glucose are higher, longer and have a greater variability than in non-diabetic subjects [2, 4] . Furthermore, because a considerable amount of time is spent in the non-fasted state, mealtime glucose excursions make a considerable contribution to overall glycaemic control [4] . If postprandial hyperglycaemia is not adequately controlled it can worsen insulin resistance and further impair insulin secretory capacity. As the early phase of insulin secretion 'primes' insulin-sensitive tissues and promotes the uptake of glucose, its restoration in patients with Type 2 diabetes is important for the control of mealtime glycaemia [5] .
The overall aim of pharmacological therapy is to control hyperglycaemia and to delay or avert microvascular and possibly macrovascular complications by maintaining long-term euglycaemia. The link between tight control of fasting glycaemia and a reduction in microvascular complications was first established in patients with Type 1 diabetes [6] and subsequently confirmed in Type 2 diabetic patients [7, 8, 9] . Although most studies did not measure postprandial glycaemia, glycosylated haemoglobin (HbA 1c ) was found to be a strong predictor of major cardiovascular events. The equal contribution made by postprandial and fasting glycaemia to HbA 1c indirectly confirms the importance of both fasting and prandial glycaemia in the prevention of complications, particularly in the early stages of the disease. Furthermore, postprandial hyperglycaemia has recently been shown to be an independent risk factor for the development of macrovascular complications [4, 10, 11] . In the Diabetes Intervention Study, intensive glucose control was associated with a lower incidence of coronary heart disease (CHD) whereas postprandial, but not fasting, hyperglycaemia was an independent risk factor for death [12] . More recently, it has been shown that HbA 1c concentrations predict mortality, with risk increasing throughout the entire range of HbA 1c concentrations, even below the threshold commonly accepted for the diagnosis of diabetes [13] .
Combination therapy for Type 2 diabetes
Dietary and lifestyle measures are fundamental for managing Type 2 diabetes. Nevertheless, apart from the stage of diabetes at diagnosis, large numbers of patients require pharmacological combination therapy to achieve good glycaemic control (HbA 1c <7%) [14] . Furthermore, because Type 2 diabetes is a progressive disease, even patients with good initial responses to monotherapy will eventually require combination treatment [7, 15, 16, 17] . The rational use of oral combination therapy can delay the need for multiple insulin injections, facilitates the maintenance of low HbA 1c and helps prevent vascular complications.
Oral antidiabetic agents can be divided into two broad categories according to their mechanism of action: those that enhance insulin secretion and those that target insulin resistance [18] (Table 1 ). Within the latter category, this effect can be achieved by increasing insulin sensitivity (e.g. thiazolidinediones, biguanides), reducing hepatic glucose production (biguanides), and delaying intestinal glucose absorption (α-glucosidase inhibitors). Because most patients with Type 2 diabetes have both impaired insulin secretion and increased insulin resistance, a rational approach is to use different classes of agents to ameliorate each defect ( Fig. 1) [18, 19] .
Combination regimens currently in use
Combination therapy has focused mainly on adding insulin-sensitizing medications to the sulfonylureas, the oldest and most widely used hypoglycaemic drugs. Sulphonylureas, previously the mainstay of treatment, provided optimal efficacy and few side effects at low dosages but, apart from their tendency to cause hypoglycaemia, can become less effective over time due to the progression of the disease (reduced insulin secretory reserve), which has led to their use in combination with insulin-sensitizers, including metformin and, more recently, thiazolidinediones. In the United Kingdom Prospective Diabetes Study (UKPDS), addition of metformin to a sulphonylurea increased the proportion of patients achieving an HbA 1c of less than 7% at 3 years: 33% in the sulphonylurea plus metformin group compared with 21% with sulphonylurea alone (p=0.007; baseline HbA 1c 7.4 and 7.3%, respectively) [15] . Also in a Swedish study, a combination therapy of glibenclamide and metformin at low doses, started relatively early after diagnosis, led to successful metabolic control with fewer side effects than on either of the respective monotherapies [20] .
Several clinical trials have shown these agents to have additive effects and no more adverse effects together than alone. The use of an α-glucosidase inhibitor in combination with sulphonylureas, metformin or insulin also results in improved glycaemic control [21, 22, 23, 24] . These agents inhibit the hydrolysis of complex carbohydrates in the gastrointestinal tract and thereby delay postprandial glucose absorption. Provided that the patients' food contains a sufficient amount of complex carbohydrates, overall α-glucosidase inhibitors are less effective in lowering FPG than sulphonylureas or metformin but are superior to the former in reducing postprandial hyperglycaemia [25] . The complementary action of α-glucosidase inhibitors with sulphonylureas in controlling both fasting and postprandial glucose concentrations was confirmed in a multicentre trial when the addition of a α-glucosidase inhibitor to tolbutamide enhanced efficacy while attenuating undesirable effects on body weight and postprandial insulin [21] . Thus, acarbose plus tolbutamide reduced HbA 1c by 0.39% more than tolbutamide alone (p<0.01).
Like the sulphonylureas, monotherapy with metformin also has a high secondary failure rate (5-10% per year) [26] as the metabolic defects in Type 2 diabetes become more pronounced over time. Its complementary mode of action with acarbose led to their use as combination therapy. The addition of acarbose to the therapeutic regimen in patients inadequately controlled with metformin and diet lowered HbA 1c , fasting and postprandial glucose as well as plasma insulin concentrations [22] . However, gastrointestinal side effects, including bloating, abdominal discomfort, diarrhoea and flatulence, which occur in up to 30% of patients treated with acarbose, frequently result in discontinuation of therapy. In one study, 56% of patients treated with acarbose plus metformin experienced gastrointestinal side effects and 12% discontinued therapy [22] . Recently, a second-generation α-glucosidase inhibitor, miglitol, has been shown to have similar effects when combined with metformin [27] , although the results are less impressive than those seen with a combination of metformin with insulin secretion enhancers.
The thiazolidinediones, rosiglitazone and pioglitazone, act by binding and activating the peroxisome proliferation-activated receptor-γ (PPAR-γ) and, unlike sulphonylureas, do not stimulate insulin release or cause hypoglycaemia [18] . These agents can reduce mean HbA 1c both as monotherapy and in combination. In one study, rosiglitazone monotherapy dose-dependently reduced mean HbA 1c by 0.8% and 1.1% at doses of 4 and 8 mg once daily, respectively, compared with placebo [28] . In combination with metformin, it improved glycaemic control, insulin sensitivity and beta-cell function. Mean HbA 1c concentrations decreased in patients treated with rosiglitazone combined with metformin 2.5 g/day (1.0% and 1.2% decrease with 4 and 8 mg/day) when compared with metformin plus placebo (p<0.001) [29] . In parallel, a dose-dependent increase in body weight was reported. Such weight gain associated with glitazone treatment Fig. 1 . Classification of antidiabetic agents according to their mechanism of action seems to be restricted to subcutaneous and not to visceral fat accumulation.
Pioglitazone in combination with metformin or sulphonylurea improved HbA 1c and FPG concentrations and produced beneficial effects on serum lipid concentrations [30, 31] . Patients receiving pioglitazone (30 mg/day) plus metformin had a mean decrease in HbA 1c (0.83% decrease) and FPG concentrations (37.7 mg/dl decrease) compared with metformin plus placebo (p≤0.05) [30] . Similar effects were observed with pioglitazone in combination with a sulphonylurea -compared with placebo, HbA 1c decreased by 0.9% in patients receiving pioglitazone 15 mg/day and 1.3% with pioglitazone 30 mg/day [31] . Further investigations are required to determine the long-term effects of these combinations.
Combination therapy can postpone the use of insulin but as the condition progresses it is usually eventually required to restore glycaemic control. If glycaemic control cannot be attained with oral combination therapy, the use of insulin, either alone or in combination with low dose oral agents, should be considered without hesitation. The efficacy of bedtime intermediate-acting insulin in combination with sulphonylurea or metformin is well documented. The combination provides a well tolerated and effective method of normalising hyperglycaemia while minimising weight gain and postponing the need for multiple injections. One study has reported that bedtime or morning insulin induces less weight gain and hyperinsulinaemia than multiple injections, while achieving the same level of glycaemic control [23] . Likewise, the long-term use of bedtime intermediate-acting insulin plus metformin gave better glycaemic control, prevented weight gain and induced less hypoglycaemia (1.8±0.4 episodes per patient) than bedtime insulin plus sulphonylurea (3.4±1.0), bedtime insulin plus sulphonylurea and metformin (3.3±1.6), or bedtime and morning insulin (3.9±1.6) [21] . Conversely, a meta-analysis of 16 studies showed that combination therapy with insulin and sulphonylurea improves glycaemic control and lowers daily insulin dosage without adversely affecting body weight [32] .
Although there are numerous treatment options, patients with Type 2 diabetes still have unmet medical needs. The reduction in efficacy over time with existing therapies and the emergence of increased postprandial glucose as an independent risk factor for vascular complications have fuelled the search for new antidiabetic medications.
New approaches to combination therapy
Restoring early-phase insulin secretion to reduce postprandial glucose excursions and prevent long-term hyperinsulinaemia is an important goal of therapy. Currently available insulin-secretion enhancers such as sulphonylureas do not have immediate effects on mealtime glucose excursions because of their slow onset of action (slow rate of absorption). Furthermore, their long duration of action confers a significant risk of hypoglycaemia unless used at low doses. For the same reasons, insulin sensitizers such as metformin do not adequately control postprandial glucose concentrations although there is some evidence showing that short-term rosiglitazone monotherapy can lower both fasting and postprandial glucose [33] .
Nateglinide and repaglinide are new, rapid-onset, short-acting insulin-secretion enhancers. These agents act directly on pancreatic beta cells to stimulate insulin release and reduce postprandial hyperglycaemia [34, 35, 36, 37, 38] . Their mode of action is complementary to agents that target insulin resistance. Repaglinide, whose action is akin to that of a short-acting sulphonylurea, when used in combination with metformin results in additive glycaemic control compared with either agent alone, reducing HbA 1c from 8.3% at baseline to 6.9% [35] . At the end of the study, 59% of patients receiving combination therapy with repaglinide and metformin achieved optimal HbA 1c concentrations of less than 7.1%. Similarly, in a randomised study of 685 Type 2 diabetic patients inadequately controlled with diet and exercise, nateglinide plus metformin additively reduced HbA 1c by 1.5% from a baseline of 8.4% [36] . Here, more than 60% of the patients receiving combination therapy achieved HbA 1c values of less than 7%,at the endpoint of the study (Fig. 2) . The additive effects of nateglinide and metformin in combination were further confirmed in a trial of 467 patients with inadequate glycaemic control, after dietary intervention (HbA 1c 6.8-11%) and despite receiving maximal metformin dosages (≥1.5 g/day) [37] . Nateglinide (60 or 120 mg before main meals) dose-dependently reduced HbA 1c with the greatest reduction being observed in patients with the highest baseline values of HbA 1c (Fig. 3) . The efficacy of combination therapy with repaglinide or nateglinide plus metformin seems to be at least comparable to the traditional combination regimens described earlier. However, no clinical studies directly comparing outcomes with new versus traditional combination regimens have been reported to date.
Given their mechanism of action, it is feasible that nateglinide or repaglinide would be more effective when used in combination with, for example, an insulin sensitizer. The thiazolidinediones, rosiglitazone and pioglitazone, do not stimulate insulin release or cause hypoglycaemia [18] making them potentially suitable candidates for combination therapy with insulin-secretion enhancers. Although troglitazone is no longer available, a combination study of troglitazone with nateglinide [38] and a similar study with repaglinide [39] both showed a reduction of HbA 1c of 1.7% which was greater than the reduction seen with the respective monotherapies in the same trials. Ongoing studies with newer, actually available glitazones will show if these previous effects are indicative of class action.
Similarly, insulin-secretion enhancers combined with α-glucosidase inhibitors should be effective in controlling postprandial hyperglycaemia. Trials investigating nateglinide plus acarbose are currently underway while others with repaglinide combined with voglibose are planned. The combination of nateglinide or repaglinide and sulphonylureas, however, is not recommended as the 'fast on-fast off' mode of action of nateglinide and repaglinide is negated by the sustained action of sulphonylureas [40] .
Adding repaglinide to NPH insulin monotherapy has recently been shown to be a possible combination therapy for patients with Type 2 diabetes, still providing a secretory reserve for insulin release [41] .
Safety and tolerability of oral antidiabetic agents
Hypoglycaemia, weight gain, adverse effects on lipid profiles, hepatotoxicity, gastrointestinal symptoms and poor compliance are the main factors limiting the use of antidiabetic agents. Of the new insulin-secretion enhancers, repaglinide is associated with a greater risk of hypoglycaemia due to its slowly reversible mode of action. Symptomatic hypoglycaemia was more common in patients receiving combination therapy with repaglinide and metformin (33%) compared with 10.7% and 0%, respectively, than with repaglinide and metformin alone. However, the majority of episodes were mild and most were reported either during titration or by one particular subject [35] . Clinical trial data indicate that nateglinide in combination seems to have a low hypoglycaemic potential; symptoms suggestive of hypoglycaemia were reported in 26% of patients receiving nateglinide and metformin in combination [36] . However, clear comparisons across different studies are difficult to make unless identical criteria are used to define and detect hypoglycaemia.
Weight gain with antidiabetic therapy is influenced by the dose, duration and efficacy of treatment. This applies to insulin secretagogues at large and also to glycerides, although their associated weight gain is minimal and reaches less than 1 kg over a 6-month study period in combination with metformin [36] . There was also no evidence of an increase in liver enzymes, atherogenic changes in plasma lipids or interaction with commonly prescribed medications [36, 42] .
Conclusions
Type 2 diabetes is a common, progressive disorder with devastating medical and social consequences [43] . There is a substantial body of evidence showing that the combination of oral antidiabetic agents with complementary mechanisms of action is highly effective in achieving and maintaining tight glycaemic control. Any effective combination therapy should improve clinical symptoms, quality of life, restore euglycaemia both in the fasting and postprandial state without inducing hypoglycaemia, and prevent or delay the development of long-term vascular complications.
Due to their short mode of action, insulin secretagogues such as repaglinide and nateglinide add new options for the management of Type 2 diabetes. The high secondary failure rate of antidiabetic monotherapy, regardless of the drug chosen, could indicate early combination therapy as a way towards better metabolic control in diabetic patients. Candidates for such early combination therapy with low doses of two oral agents, including a short acting insulin release, could be patients with HbA 1c above 8 or 9%. Such an approach could be particularly suitable in elderly Type 2 diabetic patients. Any combination therapy should be based on an understanding of the natural history and pathophysiology of Type 2 diabetes, and the complementary pharmacological action of the antidiabetic agents used.
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